Rifamycin controlled-release - Cosmo/Salix/Dr Falk Pharma

Drug Profile

Rifamycin controlled-release - Cosmo/Salix/Dr Falk Pharma

Alternative Names: Aemcolo; CB-01-11; M-14; Rifamycin controlled release; Rifamycin CR; Rifamycin SV; Rifamycin SV MMX; Rifamycin-sodium; Rifamycin-SV-sodium

Latest Information Update: 30 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cosmo Pharmaceuticals
  • Developer Cosmo Pharmaceuticals; Dr Falk Pharma; Salix Pharmaceuticals
  • Class Antibacterials; Antirheumatics; Antituberculars; Rifamycins
  • Mechanism of Action DNA-directed RNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Traveller's diarrhoea
  • Phase II Diverticulitis; Irritable bowel syndrome
  • Discontinued Clostridium-difficile-infections

Most Recent Events

  • 21 May 2018 The US FDA sets PDUFA date of November 16, 2018 for NDA review for traveller's diarrhea
  • 21 May 2018 The US FDA accepts NDA for controlled release rifamycin for Traveller's diarrhoea for review
  • 22 Mar 2018 Preregistration for Traveller's diarrhoea in European Union (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top